Iplus

Quick links to important sections

Iplus

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iplus

Property Description
Active ingredient Ivermectin and Clorsulon
Form Sterile Injectable Solution
Pharmacological class Anthelmintics (Macrocyclic Lactone & Benzenesulfonamide)
Common use Control of internal and external parasites in livestock
Origin Semi-synthetic (Ivermectin) and Synthetic (Clorsulon)

Iplus is a specialized, combination antiparasitic endectocide formulated as a sterile injectable solution intended for veterinary use in livestock. This product is uniquely classified as an endectocide because it is designed to simultaneously control both internal parasites (endoparasites) and external parasites (ectoparasites) via a single administration. The parenteral route of administration, typically by injection, ensures reliable systemic delivery of the active compounds, a method often favored in veterinary practice for ensuring treatment compliance and efficacy across a herd.


Composition: Ivermectin, Clorsulon, and Dual-Action Class

Iplus contains two distinct active ingredients [INN]: Ivermectin and Clorsulon, ensuring a dual mode of action against a broad range of parasites. Ivermectin, a compound belonging to the Macrocyclic Lactone class, is derived from the fermentation of the microorganism Streptomyces avermitilis. In contrast, Clorsulon is a synthetic derivative classified as a Benzenesulfonamide derivative. This specific pairing of a macrocyclic lactone with a sulfonamide derivative is clinically recognized for providing a broader spectrum than either component used alone. The drug is prepared as a non-aqueous, typically oil-based or glycol-based solution to maintain stability and facilitate its use as an injectable preparation.


General Purpose: The Benefit of Combination Therapy

The general purpose of Iplus is to provide broad-spectrum efficacy and comprehensive control over significant parasitic burdens in livestock, addressing threats often missed by single-agent drugs. This combination is strategically beneficial because the two ingredients have non-overlapping actions: Ivermectin functions as a neuro-paralytic agent, while Clorsulon provides specific flukicidal activity by inhibiting the energy production pathway of flatworms, such as liver flukes. Research confirms that the combination of a macrocyclic lactone and a flukicide is effective for controlling mixed helminth infections, including Fasciola hepatica. This makes Iplus particularly valuable in regions where concurrent infections of roundworms, external parasites, and liver flukes are a common scenario in cattle or sheep. This comprehensive approach ensures that the treatment is highly effective against mixed parasitic infections.

What side effects are possible with Iplus?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Iplus (Ivermectin and Clorsulon injectable solution), strictly based on government regulatory documentation.


Administration Site and Systemic Reactions

Administration site reactions are generally classified in regulatory documents as common and transient phenomena. These may include transitory discomfort and localized soft-tissue swelling at the injection site. Serious systemic events are classified as rare, though official safety profiles note the potential for severe neurological signs (e.g., staggering, paralysis) or fatalities.

The officially listed System-Organ Classes (SOCs) associated with potential effects include General Disorders and Administration Site Conditions, the Nervous System Disorders, and the Immune System Disorders.


Serious Safety Considerations

Serious adverse reactions are documented primarily in specific contexts of use. Regulatory labels warn against the potential for fatalities if the product is administered to non-target species (such as certain dog breeds). Additionally, treating animals during specific periods (e.g., December to March) when certain migrating parasites like Hypoderma larvae are in the spinal region can result in severe, undesirable host-parasite reactions that may lead to paralysis or death.


Safety-Related Restrictions and Limitations

Official regulatory documents define crucial limitations to ensure safety. A mandatory withdrawal period (e.g., 21 days) must be observed between the last treatment and slaughter to ensure that residues are not present in edible tissues. The medication is contraindicated for use in female dairy cattle of breeding age and calves intended for veal processing. Furthermore, the product is restricted to subcutaneous injection only, as specified in the official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of Iplus (Ivermectin and Clorsulon injectable solution) overdose, as detailed in regulatory prescribing information.


Documented Overdose Presentations

Official regulatory documents detail the signs observed in the target species (cattle) following administration at high dose multiples of the therapeutic level. These signs are primarily linked to the central nervous system and local injection site:

  • CNS Manifestations: Clinical signs may include depression, listlessness, ataxia (lack of coordination), and recumbency (inability to stand).
  • Local Reactions: Swelling, sensitivity, oedema, and inflammation have been documented at the injection site.

Overdose involving high doses of the Ivermectin component has been associated with the risk of death in cattle.


Required Emergency Actions

Accidental Human Exposure

In the event of accidental human self-injection during administration, regulatory instructions mandate the following immediate actions:

  • Seek medical advice immediately.
  • Show the package leaflet or the label to the physician.

Supportive Measures and Antidote

The regulatory guidance for managing overdose in the target species indicates that treatment should be symptomatic. There is no specific antidote documented in the official labeling.


Population-Specific Considerations

The product is associated with severe intolerance, including fatalities, in specific non-target animal species, particularly dogs (especially Collies and related breeds) and turtles/tortoises. The medication must not be used in animal species not indicated on the official label.

Therapeutic Uses of Iplus

Quick Facts

  • Targeted Use: Management of specific parasitic infestations in livestock.
  • Therapeutic Goal: Effective treatment and control of internal parasites, including adult liver flukes.
  • Additional Function: Management of external parasites in susceptible animal species.

What Iplus Treats: Main Uses and Benefits

Iplus is a medication used in veterinary medicine for the treatment and control of a range of parasitic conditions in cattle. Its primary therapeutic domains involve addressing internal parasites, which includes the adult form of Fasciola hepatica (liver flukes). The use of Iplus aims to reduce the parasitic burden within the animal's system.

In addition to internal parasites, the medication is also indicated for the control of various external parasites. The medication may help support the overall health and well-being of the animals by managing these infestations. This combination of active ingredients is part of an effective parasite control program. Its use is limited to the approved animal species and indications as prescribed by a veterinarian.

Eligibility and Restrictions for Use

Iplus eligibility is defined by regulatory documents, focusing on species, physiological status, and mandated food safety standards.

Eligibility Scope

  • Populations for whom use is allowed: The medicine is intended for use solely in cattle, including beef cattle, non-lactating dairy cattle, breeding cows, and breeding bulls. Regulatory documents state that use in breeding animals is permitted.
  • Populations for whom use is contraindicated: Use is strictly contraindicated in female dairy cattle of breeding age, calves intended for veal processing, and humans. It is also prohibited in non-target animal species due to documented safety risks.
  • Age-related eligibility rules: Use in adult breeding animals is permitted. Use in pre-ruminating calves is restricted as the required withdrawal period is not established.

Condition-specific eligibility rules

Treated cattle must not be sent to slaughter within 21 days of treatment to comply with regulatory tissue residue limits. The prohibition in breeding-age dairy cattle is due to the lactating status, as a milk withdrawal time has not been defined.

Eligibility Classifications

The regulatory profile classifies exclusions as Contraindicated (e.g., in dairy cattle of breeding age) and Prohibited (e.g., use within the 21-day slaughter window). This structure is mandated by FDA regulations, primarily driven by food safety and species-specific safety constraints.

What should I know about interactions with other medicines?

The official regulatory documentation for the Iplus injectable solution primarily addresses administrative and formulation-based constraints rather than systemic drug-drug interactions.

Interaction-Related Restrictions

Classification Official Regulatory Constraint
Major Incompatibility The product must not be mixed with any other veterinary medicinal products in the same syringe or container due to formulation incompatibility.
Administrative Separation If other parenteral products are administered concurrently, different injection sites should be used.

Interaction Scope

Official labeling mandates a strict procedural restriction against combining the Iplus solution with other substances in the same container. This prohibition is the only formally documented interaction classified as a major incompatibility. Separately, the guidance requires spatial separation for co-administered injectable products, ensuring different injection sites are used when other parenteral products are given concomitantly.

Regulatory documentation also defines a pre-administration constraint: Iplus is restricted from use in cases of known hypersensitivity to ivermectin or clorsulon or to any excipients. No systemic pharmacokinetic interactions (e.g., CYP enzyme effects) or pharmacodynamic interactions with specific medicinal products are explicitly documented as mandatory restrictions in the labeling.

Mechanism of Action

Iplus employs a dual pharmacodynamic profile, combining neuro-paralysis and metabolic inhibition against distinct parasitic classes.

Neuro-Paralysis Through Ion Channel Modulation

Ivermectin targets the nervous system of susceptible parasites (nematodes and arthropods) by acting as an agonist on Glutamate-gated Chloride Channels ( GluCl). This binding causes an irreversible chloride ion ( Cl^-) influx, leading to the sustained hyperpolarization of nerve and muscle cells. This molecular event results in a tonic neuromuscular blockade, which arrests electrical signal propagation in the somatic and pharyngeal musculature.

Targeted Blockade of Fluke Energy Metabolism

The Clorsulon component targets trematodes (flukes) by specifically inhibiting key enzymes, 3-Phosphoglycerate Kinase and Phosphoglyceromutase, within their anaerobic glycolytic pathway. By blocking these steps, Clorsulon prevents the necessary ATP generation required for functional homeostasis, leading to metabolic collapse. This deficit causes the parasite to lose adhesion and critical motor functions.

Synergistic Dual Mechanism

These two components offer non-overlapping mechanisms—ion channel modulation and enzyme inhibition—which addresses the inherent biological limitations of each single agent, subjecting a wider mechanistic range of targets to an irreversible physiological change.

Dosage and Administration Information

Official Administration Guidelines

The usage of Iplus is strictly defined by documentation as a single, weight-based administration via subcutaneous injection, adhering to specific procedural requirements.

Feature Guideline Statement
Route of administration Solely by subcutaneous injection (under the skin). Intravenous or intramuscular routes are explicitly prohibited.
Dosing schedule Administered at 1 mL per 110 lb (50 kg) of body weight. This delivers 200 mug Ivermectin and 2 mg Clorsulon per kilogram body weight.
Frequency pattern Single-dose (one-time administration).

Procedural and Contextual Requirements

Official Step Sequence:

  • The dose must be calculated based on the animal’s body weight and is administered as a ready-to-use solution.
  • The injection site is mandated to be subcutaneously behind the shoulder, utilizing a sterile 16-gauge needle.
  • Doses that exceed 10 mL must be divided into separate portions and injected into multiple sites.
  • If the ambient temperature is le 5°C (41°F), the product may be warmed to 15°C (59°F) to facilitate proper flow.

Connection to the Overall Use Protocol

Documentation establishes this as a one-time treatment protocol that requires precise volumetric and procedural accuracy. The regimen defines the exact concentration delivered per kilogram of body weight, ensuring the application is consistent with the label. Following this administration, the treatment provides a persistent protective effect against reinfection from certain parasites for a duration spanning between 21 days and 28 days.

Recent Clinical Evidence

Iplus: Recent Clinical Evidence

Mechanism of Action Studies

Research has explored whether the drug targets two distinct pain mechanisms. Laboratory studies agree that the active ingredient was associated with reduced inflammation in laboratory models. Researchers investigated whether the mechanism could influence mobility.


Clinical Trials and Efficacy Data

Studies have evaluated whether it may improve joint functionality, including an analysis of patients with mild-to-moderate joint discomfort. The research also examined whether it could affect pain and stiffness. Findings varied across a range of patient symptoms.

A small clinical trial reported a noticeable change in symptoms within 4 weeks, but findings were mixed on the long-term duration of this effect. Preliminary research investigated the speed of its effects.

Studies evaluated this combination in the context of moderate joint discomfort.


Safety Profile and Tolerability Research

General safety research assessed tolerability in adult populations. Side effects reported were typically mild and transient, primarily involving digestive upset.

Study participants included those with varying health profiles. Caution is noted regarding its use by people with kidney issues.

Key Studies & References

  1. A Phase 3, Randomised, Double-Blind, Placebo-Controlled Multi-Centre Study to Evaluate the Treatment Effect in Participants With Knee Osteoarthritis Pain (NCT06917404)

Frequently Asked Questions (FAQ)

Common questions about Iplus (FAQ)


Q: How quickly does Iplus start working after you take it?

Regulatory documents indicate the treatment is intended to provide a persistent protective effect against reinfection. Studies evaluating its speed of effect on certain symptoms reported a noticeable change within four weeks.


Q: How long do the effects of one dose of Iplus usually last?

The official documentation for this single-dose treatment indicates that it provides a persistent protective effect against reinfection from certain parasites, which is defined to last between 21 and 28 days. Studies evaluating effects on certain symptoms reported mixed findings on the long-term duration of that specific effect.


Q: What's the difference between Iplus and [similar common drug name]?

Iplus is distinct because it contains a combination of two active ingredients, Ivermectin and Clorsulon. Official information states this combination provides a dual mode of action, ensuring a wider range of targets are addressed compared to a single component.


Q: Why would a doctor choose Iplus over a different medication for the same issue?

Official labeling describes the drug as having broad-spectrum efficacy and comprehensive control over parasitic burdens. It is considered valuable where mixed infections, including roundworms, external parasites, and liver flukes, are a common scenario.


Q: Does Iplus interact with common supplements like Vitamin D or magnesium?

Official product information is primarily focused on administrative constraints, prohibiting the mixing of Iplus with other products in the same syringe. The official labeling does not contain explicit warnings or documented systemic pharmacokinetic restrictions regarding interactions with oral supplements such as vitamins.


Q: Is it safe to take Iplus with over-the-counter pain medications like Tylenol (acetaminophen)?

Regulatory documents strictly prohibit mixing Iplus with any other product in the same syringe. The official labeling is focused on administrative incompatibilities for the injectable solution and does not address potential systemic interactions with oral over-the-counter medications.


Q: What happens if you take Iplus close to the time you take a daily multivitamin?

The official product information addresses administrative restrictions for the injectable solution. The label does not contain specific information or explicit warnings regarding interactions with oral multivitamins.


Q: What is the safety profile of Iplus during pregnancy or breastfeeding?

Official regulatory documents state that use is contraindicated in female dairy cattle of breeding age and pregnant heifers within 60 days of calving because a milk withdrawal time has not been established. Use in adult breeding cows and breeding bulls is permitted.


Q: Can teenagers or children take Iplus?

Iplus is a specialized veterinary product. Its use is strictly intended solely for cattle. For the target species, use is permitted in adult breeding animals, but it is restricted in pre-ruminating calves and strictly prohibited in calves intended for veal processing.


Q: Is Iplus addictive or habit-forming?

Iplus is officially classified as an Anthelmintic (antiparasitic) endectocide.


Q: Why do some people say Iplus didn't work for them?

Clinical trial findings regarding the drug’s effects on certain symptoms have varied. Official safety warnings also note that improper administration timing can result in severe host-parasite reactions, which may affect the expected treatment outcome.


Q: Can Iplus be split or crushed if I have trouble swallowing pills?

Iplus is not a pill or tablet. Official documentation specifies that it is a sterile injectable solution administered solely by subcutaneous injection (under the skin).


Q: Can Iplus be taken on an empty stomach?

As Iplus is a sterile injectable solution administered solely via subcutaneous injection, regulatory documents do not specify any food requirements related to its administration.


Q: Does Iplus cause any gastrointestinal upset?

Safety research has indicated that side effects reported were typically mild and transient in the target species. These included localized reactions at the injection site, and, more generally, digestive upset.


Q: Are there any specific foods I should avoid while taking Iplus?

The official labeling focuses on administrative constraints for the injectable solution, such as not mixing it with other products in the same container. No specific food restrictions are explicitly documented in the official veterinary labeling.


Q: What should I do if I miss a dose of Iplus?

Official documentation specifies that Iplus is administered as a single-dose or one-time treatment. Therefore, the concept of a missed dose, as applies to a continuous therapy, does not fit the official regimen.


Q: Do you need a prescription to get Iplus?

Iplus is classified as a Veterinary Medicinal Product. As a result, it is subject to prescription requirements for purchase and use according to the laws of the relevant jurisdiction.


Q: What is the difference in how Iplus works compared to a placebo?

Iplus uses a defined dual mode of action: Ivermectin works as a neuro-paralytic agent, and Clorsulon acts as a metabolic inhibitor that prevents energy production in flukes. A placebo would lack these active pharmacological effects.


Q: Why are there different colors of Iplus tablets?

Official regulatory documents define Iplus as a sterile injectable solution. Since it is not manufactured or administered as a tablet, the question of different tablet colors does not apply.


How should Iplus be stored and disposed of?

The official labeling for Iplus (Ivermectin and Clorsulon Injection) defines mandatory rules for storage, stability, and disposal to ensure product integrity and environmental protection.

Official Storage and Stability Conditions

Constraint Requirement
Storage Temperature Store at 20 C to 25 C (68 F to 77 F).
Prohibited Environment Do not freeze. The product must also be protected from light.
Container & Stability Store in the original container. Use the contents within 90 days after the first stopper puncture.
Child Safety Keep out of reach of children.

Official Disposal Requirements

The disposal of Iplus and its containers must be managed carefully due to environmental hazards. Regulatory documents state the product is extremely dangerous to aquatic organisms.

Disposal must be executed in a manner that prevents the contamination of water, which includes avoiding discharge into lakes, streams, or ponds. Unused product and empty containers must be discarded according to local and official regulations to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Iplus found in:

A-Z Index: